Defining the clinical course of multiple sclerosis: the 2013 revisions
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important
for communication, prognostication, design and recruitment of clinical trials, and treatment …
for communication, prognostication, design and recruitment of clinical trials, and treatment …
The changing demographic pattern of multiple sclerosis epidemiology
N Koch-Henriksen, PS Sørensen - The Lancet Neurology, 2010 - thelancet.com
The uneven distribution of multiple sclerosis (MS) across populations can be attributed to
differences in genes and the environment and their interaction. Prevalence and incidence …
differences in genes and the environment and their interaction. Prevalence and incidence …
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview
Background: Comorbidity is an area of increasing interest in multiple sclerosis (MS).
Objective: The objective of this review is to estimate the incidence and prevalence of …
Objective: The objective of this review is to estimate the incidence and prevalence of …
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
Background Interferon beta reduces activity in multiple sclerosis as measured clinically and
by magnetic resonance imaging (MRI). We assessed the effect of interferon beta-1a on the …
by magnetic resonance imaging (MRI). We assessed the effect of interferon beta-1a on the …
[HTML][HTML] A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
G Giovannoni, G Comi, S Cook… - … England Journal of …, 2010 - Mass Medical Soc
Background Cladribine provides immunomodulation through selective targeting of
lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral …
lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral …
Factors influencing success of clinical genome sequencing across a broad spectrum of disorders
To assess factors influencing the success of whole-genome sequencing for mainstream
clinical diagnosis, we sequenced 217 individuals from 156 independent cases or families …
clinical diagnosis, we sequenced 217 individuals from 156 independent cases or families …
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Natalizumab, a highly specific α4-integrin antagonist, is approved for treatment of patients
with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for …
with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for …
Evolving concepts in the treatment of relapsing multiple sclerosis
G Comi, M Radaelli, PS Sørensen - The Lancet, 2017 - thelancet.com
In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The
increasing availability of effective disease-modifying therapies has shifted the aim of …
increasing availability of effective disease-modifying therapies has shifted the aim of …
Immunogenicity of interferon‐β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration
C Ross, KM Clemmesen, M Svenson… - Annals of …, 2000 - Wiley Online Library
A total of 754 consecutive patients with relapsing‐remitting multiple sclerosis were
investigated for interferon‐β (IFNβ) antibodies by protein‐G affinity chromatography and …
investigated for interferon‐β (IFNβ) antibodies by protein‐G affinity chromatography and …
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis
(MS). Treatment with natalizumab has been associated with progressive multifocal …
(MS). Treatment with natalizumab has been associated with progressive multifocal …